Company
(Symbol)#*

Date filed

Shares/Units (M)

Price

Shares out

Lead, other underwriters

Gross (US$M)


Adalta Ltd. (Melbourne, Australia; ASX)1

7/12/16

N/A

N/A

N/A

N/A

$7.55

Adienne Pharma & Biotech SA (Lugano, Switzerland; Swiss Stock Exchange)

9/15/16

N/A

N/A

N/A

N/A

N/A

Advanced Inhalation Therapies Ltd. (Tel Aviv, Israel; AITP)2

8/27/15

0.675U

$15

2.3

Joseph Gunnar & Co.

$10.125

Anaptysbio Inc. (San Diego; ANAB)

9/9/15

N/A

N/A

N/A

Credit Suisse; Stifel; JMP Securities; Wedbush Securities

$86.25

Anterios Inc. (New York; ANTE)

4/2/15

3.9S

$12-$14

13.5

Stifel (co-lead); RBC Capital Markets (co-lead); JMP Securities; Needham & Co.

$50.7

Azurrx Biopharma Inc. (Brooklyn, N.Y.; AZRX)

7/15/16

1.2S

$5.50

N/A

Wallachbeth Capital; Network 1 Financial Securities

$6.60

Biolight Life Sciences Ltd. (Tel Aviv, Israel; BOLT)3

2/10/16

1.848S and W for 1.848S

N/A

4.45

Feltl and Co.; Rodman & Renshaw

$10.00

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.; NYSE:CPP)

12/24/15

1.92S

$12-$14

7.42

Aegis Capital; Maxim Group

$24.96

Crispr Therapeutics AG (Cambridge, Mass.; CRSP)4

9/13/16

N/A

N/A

N/A

Citigroup Global Markets; Piper Jaffray; Barclays Capital

$90

Gan & Lee Pharmaceuticals Ltd. (China)5

6/15/16

N/A

N/A

N/A

N/A

$227.00

Lumena Pharmaceuticals Inc. (San Diego; LIVR)

4/2/14

N/A

N/A

N/A

Citigroup (co-lead); Cowen and Co. (co-lead); Leerink Partners (co-lead)

$75.00

Mapi-Pharma Ltd. (Ness Ziona; MAPI)

1/26/16

3.125S

$15-$17

11.76

JMP Securities; FBR; Maxim Group

$50

Motif Bio plc (London and New York; MTFB)

7/14/16

28S

$12.42

N/A

Suntrust Robinson Humphrey; Ladenburg Thalmann

$35.00

Myovant Sciences Ltd. (Hamilton, Bermuda)

10/4/16

N/A

N/A

N/A

Citigroup; Cowen and Co.; Evercor ISI; Barclays

$172.50

Nant Health LLC (Culver City, Calif.; NH)

5/25/16

6.5S

$12.50-$15.50

N/A

N/A

$91.00

Ra Pharmaceuticals Inc. (Cambridge, Mass.; RARX)

10/4/16

N/A

N/A

N/A

Credit Suisse; Jefferies; BMO Capital Markets; Suntrust Robinson Humphrey

$86

Samsung Biologics Co. Ltd. (subsidiary of Samsung Group; KOSPI)6

8/16/16

N/A

N/A

N/A

N/A

$1.8B to $2.7B

Thar Pharmaceuticals Inc. (Pittsburgh; THAR)

8/23/16

N/A

N/A

N/A

Suntrust Robinson Humphrey

$50

Tigenix NV (Leuven, Belgium; TIG)7

12/24/15

ADS

N/A

N/A

Canaccord Genuity; Nomura; KBC Securities; Chardan Capital Markets

N/A

Visterra Inc. (Cambridge, Mass.; VIST)

1/5/16

N/A

N/A

N/A

Leerink Partners; Stifel; Needham & Co.; Wedbush Pacgrow

$69.00

Viventia Bio Inc. (Winnipeg, Manitoba; VITA)

10/21/15

N/A

N/A

N/A

Leerink Partners; Cowen and Co.; Guggenheim Securities

$86.25


Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.

This chart includes only biotech companies that develop therapeutics.

1 Adalta plans to raise up to A$10M (US$7.55M) in an IPO on the Australian Securities Exchange.

2 Advanced Inhalation's units each consist of two ordinary shares and three warrants each to purchase one ordinary share.

3 Biolight applied to list its shares for the first time in the U.S., although it already trades on the Tel Aviv Stock Exchange under the symbol "BOLT."

4 Crispr Therapeutics said it granted underwriters an option to purchase additional shares to cover overallotments. Crispr also disclosed that, concurrent with the offering, existing shareholder Bayer Global Investments BV, an affiliate of its joint venture partner, Bayer Healthcare LLC, agreed to purchase $35M in shares from the company at the IPO price in a private placement.

5 Gan & Lee plans to raise nearly ¥1.5B (US$227B) in an IPO in China.

6 Samsung filed for an IPO on the main board of the South Korea Stock Exchange and is expected to raise between SKW2 trillion to SKW3 trillion (US$1.8B to $2.7B).

7 Tigenix filed a Form F-1 for a proposed IPO of its American Depository Shares to be listed on Nasdaq. The company's ordinary shares are currently listed on Euronext Brussels.

 

 

No Comments